In Brief: SmithKline Beecham Tagamet
SmithKline Beecham Tagamet: Company will present drug interaction data on cimetidine to joint meeting of FDA's Nonprescription Drug and Gastrointestinal Drugs Advisory Committees during afternoon session of March 27 meeting. The meeting will take place in conference rooms D & E of FDA's Parklawn Building beginning at 1 p.m. SB maintains that the data will show that Tagamet has no clinically significant interactions with other drugs at the proposed OTC dose. Committee concerns about possible interactions resulted in a negative vote on the Rx-to-OTC switch application in July...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth